Fetal Chromosomal Aneuploidy (T21, T18, T13) Test Kit (reversible termination sequencing)

NIPT is a prenatal screening method that uses high-throughput gene sequencing and molecular genetic techniques to detect fetal cell-free DNA fragments in maternal peripheral blood, assessing the risk of common fetal chromosomal aneuploidies (T21, T18, T13). The test extracts free DNA from maternal blood containing fetal genetic information and analyzes it through high-throughput sequencing to detect abnormalities in fetal chromosome number and structure. Compared to traditional maternal serum screening, NIPT offers advantages of high detection rate and low false positive rate, while avoiding the risks associated with invasive methods such as amniocentesis.

A comprehensive solution for prenatal testing including reagent kits and equipment for DNA sequencing and bioinformatic analysis. Sensitivity greater than 99% for detection of trisomies 21, 18, and 13, with capability to identify up to 100 genetic conditions and produce results within 14 hours.

A non-invasive prenatal test that analyzes fetal DNA from maternal blood using Next Generation Sequencing (NGS) technology. The test can be performed as early as 10 weeks of pregnancy with detection rates exceeding 99% accuracy. It is the first in Korea to analyze chromosomes 9, 16, and 22, as well as microdeletions, and eliminates the miscarriage risk associated with invasive procedures such as amniocentesis or chorionic villus sampling.